Baculoviruses as gene therapy vectors for human prostate cancer

Journal of Invertebrate Pathology

Volumn 107, Issue SUPPL., 2011, Pages

  Rivera Gonzalez, Guillermo C ^a   Swift, Stephanie L ^a   Dussupt, Vincent ^a   Georgopoulos, Lindsay J ^a   Maitland, Norman J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Baculovirus vectors; Gene therapy; Prostate cancer

Indexed keywords

GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; MALE; METHODOLOGY; PATHOGENICITY; POLYHEDROSIS VIRUS; PROSTATE TUMOR; REVIEW;

GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; NUCLEOPOLYHEDROVIRUS; PROSTATIC NEOPLASMS;

AUTOGRAPHA CALIFORNICA MNPV; AUTOGRAPHA CALIFORNICA NUCLEOPOLYHEDROVIRUS;

EID: 79960629008     PISSN: 00222011     EISSN: 10960805     Source Type: Journal    
DOI: 10.1016/j.jip.2011.05.006     Document Type: Review

References (104)

1. Airenne K.J., Makkonen K.E., Mahonen A.J., Yla-Herttuala S. In vivo application and tracking of baculovirus. Curr. Gene Ther. 2010, 10:187-194.
2. Bahk J.Y., Hyun J.S., Lee B.H., Kim M.O., Cho G.J., Choi W.S. Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol. Res. 1998, 26:259-264.
3. Batra R.K., Olsen J.C., Pickles R.J., Hoganson D.K., Boucher R.C. Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors. Am. J. Respir. Cell Mol. Biol. 1998, 18:402-410.
4. Birnie R., Bryce S.D., Roome C., Dussupt V., Droop A., Lang S.H., Berry P.A., Hyde C.F., Lewis J.L., Stower M.J., Maitland N.J., Collins A.T. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008, 9:R83.
5. Blissard G.W., Wenz J.R. Baculovirus gp64 envelope glycoprotein is sufficient to mediate pH-dependent membrane fusion. J. Virol. 1992, 66:6829-6835.
6. Boyce F.M., Bucher N.L. Baculovirus-mediated gene transfer into mammalian cells. Proc. Natl. Acad. Sci. USA 1996, 93:2348-2352.
7. Bridgewater J.A., Springer C.J., Knox R.J., Minton N.P., Michael N.P., Collins M.K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 1995, 31A:2362-2370.
8. Bridgewater J.A., Knox R.J., Pitts J.D., Collins M.K., Springer C.J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 1997, 8:709-717.
9. Brookes D.E., Zandvliet D., Watt F., Russell P.J., Molloy P.L. Relative activity and specificity of promoters from prostate-expressed genes. Prostate 1998, 35:18-26.
10. Burges H.D., Croizier G., Huber J. A review of safety tests on baculoviruses. BioControl 1980, 25:329-339.
11. Cheng W.S., Kraaij R., Nilsson B., van der Weel L., de Ridder C.M., Totterman T.H., Essand M. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol. Ther. 2004, 10:355-364.
12. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., Hussain S., Murray P.I., Searle P., Seymour L., Harris P.A., Ferry D., Kerr D.J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7:2662-2668.
13. Clark J., Attard G., Jhavar S., Flohr P., Reid A., De Bono J., Eeles R., Scardino P., Cuzick J., Fisher G., Parker M.D., Foster C.S., Berney D., Kovacs G., Cooper C.S. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008, 27:1993-2003.
14. Cleutjens K.B., van Eekelen C.C., van der Korput H.A., Brinkmann A.O., Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 1996, 271:6379-6388.
15. Cui W., Gusterson B., Clark A.J. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Ther. 1999, 6:764-770.
16. Cussenot O., Berthon P., Berger R., Mowszowicz I., Faille A., Hojman F., Teillac P., Le Duc A., Calvo F. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J. Urol. 1991, 146:881-886.
17. Daneshmand S., Quek M.L., Lin E., Lee C., Cote R.J., Hawes D., Cai J., Groshen S., Lieskovsky G., Skinner D.G., Lee A.S., Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol. 2007, 38:1547-1552.
18. Danielsson A., Dzojic H., Nilsson B., Essand M. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther. 2008, 15:203-213.
19. Dondi D., Limonta P., Moretti R.M., Marelli M.M., Garattini E., Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res. 1994, 54:4091-4095.
20. Drabek D., Guy J., Craig R., Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 1997, 4:93-100.
21. Dubbink H.J., Verkaik N.S., Faber P.W., Trapman J., Schroder F.H., Romijn J.C. Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem. J. 1996, 315:901-908.
22. Dubbink H.J., de Waal L., van Haperen R., Verkaik N.S., Trapman J., Romijn J.C. The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterization. Genomics 1998, 51:434-444.
23. Dubbink H.J., Cleutjens K.B., van der Korput H.A., Trapman J., Romijn J.C. An Sp1 binding site is essential for basal activity of the human prostate-specific transglutaminase gene (TGM4) promoter. Gene 1999, 240:261-267.
24. Dubbink H.J., Hoedemaeker R.F., van der Kwast T.H., Schroder F.H., Romijn J.C. Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern. Lab. Invest. 1999, 79:141-150.
25. Dzojic H., Cheng W.S., Essand M. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model. Cancer Gene Ther. 2007, 14:233-240.
26. Gao R., McCormick C.J., Arthur M.J., Ruddell R., Oakley F., Smart D.E., Murphy F.R., Harris M.P., Mann D.A. High efficiency gene transfer into cultured primary rat and human hepatic stellate cells using baculovirus vectors. Liver 2002, 22:15-22.
27. Georgopoulos L.J., Elgue G., Sanchez J., Dussupt V., Magotti P., Lambris J.D., Totterman T.H., Maitland N.J., Nilsson B. Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood. Mol. Immunol. 2009, 46:2911-2917.
28. Gleason, D.F., 1966. Classification of prostatic carcinomas. Cancer Chemother. Rep. Part 1(50), 125-128.
29. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 1329:568-571.
30. Good D., Schwarzenberger P., Eastham J.A., Rhoads R.E., Hunt J.D., Collins M., Batzer M., Theodossiou C., Kolls J.K., Grimes S.R. Cloning and characterization of the prostate-specific membrane antigen promoter. J. Cell Biochem. 1999, 74:395-405.
31. Grohmann M., Paulmann N., Fleischhauer S., Vowinckel J., Priller J., Walther D.J. A mammalianized synthetic nitroreductase gene for high-level expression. BMC Cancer 2009, 9:301.
32. Hitchman R.B., Murguía-Meca F., Danquah J., King L.A. Baculovirus as vectors for human cells and applications in organ transplantation. J. Invertebr. Pathol. 2011, 107:S49.
33. Hoare J., Waddington S., Thomas H.C., Coutelle C., McGarvey M.J. Complement inhibition rescued mice allowing observation of transgene expression following intraportal delivery of baculovirus in mice. J. Gene Med. 2005, 7:325-333.
34. Hofmann C., Sandig V., Jennings G., Rudolph M., Schlag P., Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc. Natl. Acad. Sci. USA 1995, 92:10099-10103.
35. Hofmann C., Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 1998, 5:531-536.
36. Hu Y.C. Baculovirus vectors for gene therapy. Adv. Virus Res. 2006, 68:287-320.
37. Hüser A., Rudolph M., Hofmann C. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat. Biotechnol. 2001, 19:451-455.
38. Kadlec J., Loureiro S., Abrescia N.G., Stuart D.I., Jones I.M. The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. Nat. Struct. Mol. Biol. 2008, 15:1024-1030.
39. Kaikkonen M.U., Maatta A.I., Yla-Herttuala S., Airenne K.J. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. Mol. Ther. 2010, 18:987-992.
40. Kaikkonen M.U., Ylä-Herttuala S., Airenne K.J. How to avoid complement attack in baculovirus-mediated gene delivery. J. Invertebr. Pathol. 2011, 107:S71.
41. Kaname Y., Tani H., Kataoka C., Shiokawa M., Taguwa S., Abe T., Moriishi K., Kinoshita T., Matsuura Y. Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64. J. Virol. 2010, 84:3210-3219.
42. Kitagawa Y., Tani H., Limn C.K., Matsunaga T.M., Moriishi K., Matsuura Y. Ligand-directed gene targeting to mammalian cells by pseudotype baculoviruses. J. Virol. 2005, 79:3639-3652.
43. Koppan M., Nagy A., Schally A.V., Plonowski A., Halmos G., Arencibia J.M., Groot K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999, 38:151-158.
44. Kukkonen S.P., Airenne K.J., Marjomaki V., Laitinen O.H., Lehtolainen P., Kankaanpaa P., Mahonen A.J., Raty J.K., Nordlund H.R., Oker-Blom C., Kulomaa M.S., Yla-Herttuala S. Baculovirus capsid display: a novel tool for transduction imaging. Mol. Ther. 2003, 8:853-862.
45. Laakkonen J.P., Kaikkonen M.U., Ronkainen P.H., Ihalainen T.O., Niskanen E.A., Hakkinen M., Salminen M., Kulomaa M.S., Yla-Herttuala S., Airenne K.J., Vihinen-Ranta M. Baculovirus-mediated immediate-early gene expression and nuclear reorganization in human cells. Cell Microbiol. 2008, 10:667-681.
46. Latham J.P., Searle P.F., Mautner V., James N.D. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000, 60:334-341.
47. Lee S.J., Kim H.S., Yu R., Lee K., Gardner T.A., Jung C., Jeng M.H., Yeung F., Cheng L., Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol. Ther. 2002, 6:415-421.
48. Limonta P., Dondi D., Moretti R.M., Fermo D., Garattini E., Motta M. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J. Clin. Endocrinol. Metab. 1993, 76:797-800.
49. Leuschner C., Enright F.M., Gawronska-Kozak B., Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003, 56:239-249.
50. Liu A.Y., True L.D. Characterization of prostate cell types by CD cell surface molecules. Am. J. Pathol. 2002, 160:37-43.
51. Macintosh C.A., Stower M., Reid N., Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 1998, 58:23-28.
52. MacRae E.J., Giannoudis A., Ryan R., Brown N.J., Hamdy F.C., Maitland N., Lewis C.E. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006, 66:470-494.
53. Maitland, N.J., 2008. Pathobiology of the human prostate. Trends in Urology Gynaecology & Sexual Health, July/August.
54. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 2008, 26:2862-2870.
55. Maitland N., Chambers K., Georgopoulos L., Simpson-Holley M., Leadley R., Evans H., Essand M., Danielsson A., van Weerden W., de Ridder C., Kraaij R., Bangma C.H., GIANT FP6 Consortium Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems? Hum. Gene Ther. 2010, 7:815-827.
56. Makela A.R., Enback J., Laakkonen J.P., Vihinen-Ranta M., Laakkonen P., Oker-Blom C. Tumor targeting of baculovirus displaying a lymphatic homing peptide. J. Gene Med. 2008, 10:1019-1031.
57. Martiniello-Wilks R., Wang X.Y., Voeks D.J., Dane A., Shaw J.M., Mortensen E., Both G.W., Russell P.J. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J. Gene Med. 2004, 6:1343-1357.
58. Matilainen H., Makela A.R., Riikonen R., Saloniemi T., Korhonen E., Hyypia T., Heino J., Grabherr R., Oker-Blom C. RGD motifs on the surface of baculovirus enhance transduction of human lung carcinoma cells. J. Biotechnol. 2006, 125:114-126.
59. McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am. J. Surg. Pathol. 1988, 12:897-906.
60. Merrihew R.V., Clay W.C., Condreay J.P., Witherspoon S.M., Dallas W.S., Kost T.A. Chromosomal integration of transduced Recombinant baculovirus DNA in mammalian cells. J. Virol. 2001, 75:903-909.
61. Nagy A., Schally A.V. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol. Reprod. 2005, 73:851-859.
62. Noss K.R., Wolfe S.A., Grimes S.R. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 2002, 285:247-256.
63. O'Keefe D.S., Su S.L., Bacich D.J., Horiguchi Y., Luo Y., Powell C.T., Zandvliet D., Russell P.J., Molloy P.L., Nowak N.J., Shows T.B., Mullins C., Vonder Haar R.A., Fair W.R., Heston W.D. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta 1998, 1443:113-127.
64. Oudes A.J., Campbell D.S., Sorensen C.M., Walashek L.S., True L.D., Liu A.Y. Transcriptomes of human prostate cells. BMC Genom. 2006, 7:92.
65. Palmer D.H., Milner A.E., Kerr D.J., Young L.S. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br. J. Cancer 2003, 89:944-950.
66. Palmer D.H., Mautner V., Mirza D., Oliff S., Gerritsen W., van der Sijp J.R., Hubscher S., Reynolds G., Bonney S., Rajaratnam R., Hull D., Horne M., Ellis J., Mountain A., Hill S., Harris P.A., Searle P.F., Young L.S., James N.D., Kerr D.J. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 2004, 22:1546-1552.
67. Paul A., Jardin B.A., Kulamarva A., Malhotra M., Elias C.B., Prakash S. Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization. Mol. Biotechnol. 2010, 45:129-139.
68. Pályi I., Vincze B., Lovas S., Mezo I., Pató J., Kálnay A., Turi G., Gaál D., Mihalik R., Péter I., Teplán I., Murphy R.F. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc. Natl. Acad. Sci. USA 1999, 96:2361-2366.
69. Pienta K.J., Abate-Shen C., Agus D.B., Attar R.M., Chung L.W., Greenberg N.M., Hahn W.C., Isaacs J.T., Navone N.M., Peehl D.M., Simons J.W., Solit D.B., Soule H.R., Vandyke T.A., Weber M.W., Wu L., Vessella R.L. The current state of preclinical prostate cancer animal models. Prostate 2008, 68:629-639.
70. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol. Aspects Med. 2007, 28:4-41.
71. Raty J.K., Airenne K.J., Marttila A.T., Marjomaki V., Hytonen V.P., Lehtolainen P., Laitinen O.H., Mahonen A.J., Kulomaa M.S., Yla-Herttuala S. Enhanced gene delivery by avidin-displaying baculovirus. Mol. Ther. 2004, 9:282-291.
72. Russell D.W., Miller A.D., Alexander I.E. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 1994, 91:8915-8919.
73. Sakr W.A., Grignon D.J., Haas G.P., Heilbrun L.K., Pontes J.E., Crissman J.D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur. Urol. 1996, 30:138-144.
74. Salem M., Garcia J.A. Abiraterone acetate: a novel adrenal inhibitor in metastatic castration-resistant prostate cancer Current. Oncol. Rep. 2011, 13:92-96.
75. Sandig V., Hofmann C., Steinert S., Jennings G., Schlag P., Strauss M. Gene transfer into hepatocytes and human liver tissue by baculovirus vectors. Hum. Gene Ther. 1996, 7:1937-1945.
76. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L., Halmos G. Hypothalamic hormones and cancer. Front. Neuroendocrin. 2001, 22:248-291.
77. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005, 23:8253-8261.
78. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer A., Määttänen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A., Investigators E.R.S.P.C. Screening and prostate-cancer mortality in a randomized European study. New Engl. J. Med. 2009, 26:1320-1328.
79. Schuster S.C. Next-generation sequencing transforms today's biology. Nat. Methods 2008, 5:16-18.
80. Schuur E.R., Henderson G.A., Kmetec L.A., Miller J.D., Lamparski H.G., Henderson D.R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 1996, 271:7043-7051.
81. Searle P.F., Chen M.J., Hu L., Race P.R., Lovering A.L., Grove J.I., Guise C., Jaberipour M., James N.D., Mautner V., Young L.S., Kerr D.J., Mountain A., White S.A., Hyde E.I. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. 2004, 31:811-816.
82. Seethalakshmi L., Mitra S.P., Dobner P.R., Menon M., Carraway R.E. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997, 31:183-192.
83. Stanbridge L.J., Dussupt V., Maitland N.J. Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer. J. Biomed. Biotechnol. 2003, 2003:79-91.
84. Sugimura, Y., Cunha, G.R., Donjacour, A.A., 1986. Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol. Reprod. 34(5), 973-983.
85. Swift S.L., Burns J.E., Maitland N.J. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res. 2010, 70:347-356.
86. Taplin M.E., Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell Biochem. 2004, 15:483-490.
87. Tieva Å., Wikström P., Olofsson J.I., Bergh A., Damber J.-E. Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1999, 39:101-107.
88. Tieva Å., Stattin P., Wikström P., Bergh A., Damber J.-E. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001, 47:276-284.
89. Tsai C.T., Chuang C.K., Hu Y.C. Baculovirus-mediated gene transfer into mesenchymal stem cells. Methods Mol. Biol. 2009, 515:339-351.
90. Tubiana M., Malaise E. Comparison of cell proliferation kinetics in human and experimental tumors: response to irradiation. Cancer Treat. Rep. 1976, 60:1887-1895.
91. van Loo N.D., Fortunati E., Ehlert E., Rabelink M., Grosveld F., Scholte B.J. Baculovirus infection of nondividing mammalian cells: mechanisms of entry and nuclear transport of capsids. J. Virol. 2001, 75:961-970.
92. van Oers M.M. Opportunities and challenges for the baculovirus expression system. J. Invertebr. Pathol. 2011, 107:S3.
93. van Weerden W.M., de Ridder C.M., Verdaasdonk C.L., Romijn J.C., van der Kwast T.H., Schroder F.H., van Steenbrugge G.J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 1996, 149:1055-1062.
94. Verma F.M., Weitzman M.D. Gene therapy: twenty first century medicine. Ann. Rev. Biochem. 2005, 74:711-738.
95. Vicente T., Peixoto C., Carrondo M.J., Alves P.M. Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther. 2009, 16:766-775.
96. Washburn J.O., Chan E.Y., Volkman L.E., Aumiller J.J., Jarvis D.L. Early synthesis of budded virus envelope fusion protein GP64 enhances Autographa californica multicapsid nucleopolyhedrovirus virulence in orally infected Heliothis virescens. J. Virol. 2003, 77:280-290.
97. Washburn J.O., Lyons E.H., Haas-Stapleton E.J., Volkman L.E. Multiple nucleocapsid packaging of Autographa californica nucleopolyhedrovirus accelerates the onset of systemic infection in Trichoplusia ni. J. Virol. 1999, 73:411-416.
98. Watt F., Martorana A., Brookes D.E., Ho T., Kingsley E., O'Keefe D.S., Russell P.J., Heston W.D., Molloy P.L. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001, 73:243-254.
99. Webber M.M., Bello D., Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 1997, 30:58-64.
100. Weedon S.J., Green N.K., McNeish I.A., Gilligan M.G., Mautner V., Wrighton C.J., Mountain A., Young L.S., Kerr D.J., Searle P.F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int. J. Cancer 2000, 86:848-854.
101. Wilson W.R., Pullen S.M., Hogg A., Helsby N.A., Hicks K.O., Denny W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002, 62:1425-1432.
102. Wright G.L., Grob B.M., Haley C., Grossman K., Newhall K., Petrylak D., Troyer J., Konchuba A., Schellhammer P.F., Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48:326-334.
103. Yang W.H., Wieczorck M., Allen M.C., Nett T.M. Cytotoxic activity of Gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. Endocrinology 2003, 144:1456-1463.
104. Zeng J., Du J., Zhao Y., Palanisamy N., Wang S. Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells 2007, 25:1055-1061.